anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lifestyle factors playing a role in the development of late-life cognitive decline may be modifiable. There is a need for robust evidence about the potential for prevention of cognitive decline through behavior change interventions.

This study involves the development, implementation and initial testing of a behavior change intervention. At the 1st year, a small-scale randomized controlled trial (RCT) will investigate the implementation of a goal-setting intervention aim at promoting behavior change of personal modifiable risks for cognitive decline in the community for \>55 years with at least one of the 7 modifiable risk factors for dementia. These older participants in the community (n = 100) will be randomized to either control (had a discussion regarding health and daily activity) or goal-setting with mentoring (the goal-setting interview involving identification of up to five personal goals of personal modifiable risks). All participants will be reassessed after 12 months. The 2nd to the 5th year, is a multisite, prospective, RCT with 36 months intervention. Recruitment of 300 older people (≥55 years) with at least one of the 7 modifiable risk factors for dementia will take place in Northern Taiwan. Participants randomised to the intervention condition will have access to an interactive internet platform, stimulating self-management of dementia risk factors, with remote mentoring by a mentor.
NEW MATERIAL:1-Carboxy-2-(3,4-dihydroxyphenyl)ethyl (E)-3-[3- hydroxy-4-[[2-(3,4-dihydroxyphenyl)-1-methoxycarbonyl]vinyloxy]phenylp henyl]- propenoate of formula. USE:Useful as an anti-inflammatory agent having improved activity. PREPARATION:KEIGAI (leaf and stalk of Schizonepeta tenuifolia) is extracted by infusing with a cold mixture of acetone and water. The mixing ratio of acetone to water is usually 7:3 (V/V), 3-4 liter of the mixture is used in one extraction step of 1kg of KEIGAI and the cold extraction is repeated 3-4 times to obtain an extracted liquid. The acetone in the extracted liquid is distilled off under reduced pressure to obtain an aqueous solution, which is washed 4-6 times with chloroform. The obtained aqueous layer is extracted with ethyl acetate, the extracted liquid is concentrated under reduced pressure and the extract is separated and purified by column chromatography to obtain the objective compound of formula.
Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
OBJECTIVES: The urban environment can have a significant impact on mental and physical health. Health impact appraisal of new developments should address these issues. However, transferable economic valuation evidence for urban planners in the United Kingdom is thin, especially around mental health, making it harder to estimate the cost-efficiency of public health interventions to address these conditions. A further complication is that mental health may be perceived differently from physical health. This study examines willingness to pay (WTP) to avoid depression and lower back pain.
METHODS: WTP estimates were obtained by applying contingent valuation tasks in an online survey with a representative sample in the United Kingdom (N = 1553). Interval regression models were used to estimate the effects of disease severity, payment frequency, and respondent characteristics on WTP.
RESULTS: Respondents' WTP to avoid both conditions was relatively high (around 5%-6% of stated income to return to current health state). Depression was rated as being twice as burdensome on quality of life than pain, and bids to avoid depression were 20% to 30% more than pain. Analysis of motivation responses suggests mental health treatment is perceived as less easy to access and less effective than the equivalent for pain, and respondents expect a larger burden on their family and relationships as they try to manage their condition themselves.
CONCLUSIONS: Results suggest that depression bids may be affected by uncertainty around access to effective treatment in the healthcare system. This has implications for how mental illness may be prioritized in resource allocation toward public health interventions.
Lymph node metastasis (LNM) is a typical marker in oral squamous cell carcinoma (OSCC) indicating poor prognosis. Pathological examination by artificial image acquisition and analysis, as the main diagnostic method for LNM, often takes a week or longer which may cause great anxiety of the patient and also retard timely treatment. However, there are few efficient fast LNM diagnosis methods in clinical applications currently. Our previous study profiled the proteomics of extracellular vesicles (EVs) derived from postoperative drainage fluid (PDF) and showed the potential of detecting specific EVs that expressed aspartate β-hydroxylase (ASPH) for LNM diagnosis in OSCC patients. Considering that the analysis of ASPH+ PDF-EVs is challenging due to their low abundance (counting less than 10% of total EVs in PDF) and the complex EV isolation process of ultra-centrifugation, we developed a facile platform containing two microfluidic chips filled with antibody-modified microbeads to isolate ASPH+ PDF-EVs, with both the capture and retrieval rate reaching around 90%. Clinical sample analysis based on our method revealed that a mean of 6 × 106 /mL ASPH+ PDF-EVs could be isolated from LNM+ OSCC patients compared to 2.5 × 106 /mL in LNM- OSCC ones. When combined with enzyme-linked immunosorbent assay (ELISA) technique that was commonly used in clinical laboratories in hospitals, this microfluidic platform could precisely distinguish postoperative OSCC patients with LNM or not in several hours, which were validated by a double-blind test containing 6 OSCC patients. We believe this strategy has promise for early diagnosis of LNM in postoperative OSCC patients and finally helps guiding timely and reasonable treatment in clinic.
PROBLEM TO BE SOLVED: To obtain an easily disintegrable soft agglomerate powder which is excellent in slip and rolling properties and gives cosmetics having good usability, functional characteristics, etc., by coating the surface of a powder having a specified particle size with a liq. oil and a solid org. substance. SOLUTION: This powder is obtd. by coating the surface of a powder (e.g. a powder conventionally used for cosmetics, such as Yellow No.4, a nylon powder, or titanium oxide) having an average particle size of 0.001-15μm with a liq. oil (e.g. dimethylpolysiloxane) and a solid org. susbtance (e.g. N-lauroyl-L- lysine) and pref. has such a cohesive strength that, when 1 pt.wt. this powder is put into 100 pts.wt. ethanol, immediately subjected to ultrasonic dispersion, and measured after 0.5min and 30min from the beginning of the ultrasonic dispersion with a particle size distribution meter of a laser diffraction type, the ratio of 50vol.% cummulative particle size (D50) after 30min to that after 0.5min, D50 (after 30min)/D50 (after 0.5min), is in the range of 0.01-0.6.
Use of a BCL-2 inhibitor in the preparation of a medicament for treating an aging-related skin disease. A medicament for treating an aging-related skin disease, characterized by comprising a pharmaceutically effective amount of the BCL-2 inhibitor. The BCL-2 inhibitor is an inhibitor that inhibits a member of the BCL-2 anti-apoptotic protein family. The member of the BCL-2 anti-apoptotic protein family is at least one selected from BCL-2, BCL-xL and BCL-w. The BCL-2 inhibitor is at least one selected from ABT -737 and ABT-263. The pharmaceutical formulation is at least one of an injection formulation or an external formulation. The aging-related skin disease is at least one selected from: eczema, psoriasis, hyperpigmentation, nevi, rashes, atopic dermatitis, urticaria, photoallergy or photoaging-related diseases and conditions, and wrinkles; pruritus; dysesthesia; eczema outbreak; eosinophilic skin diseases; reactive neutrophilic skin disease; pemphigus; pemphigoid; immune bullous skin diseases; skin fibroblast proliferation; keloids; cutaneous lymphoma; and skin diseases or conditions of cutaneous lupus.
Among the most prevalent neurodevelopmental disorders, Autism Spectrum Disorder (ASD) is highly diverse showing a broad phenotypic spectrum. ASD also couples with a broad range of mutations, both de novo and inherited. In this study, we used a proprietary SNP genotyping chip to analyze the genomic DNA of 250 Vietnamese children diagnosed with ASD. Our Single Nucleotide Polymorphism (SNP) genotyping chip directly targets more than 800 thousand SNPs in the genome. Our primary focus was to identify pathogenic/likely pathogenic mutations that are potentially linked to more severe symptoms of autism. We identified and validated 23 pathogenic/likely pathogenic mutations in this initial study. The data shows that these mutations were detected in several cases spanning multiple biological pathways. Among the confirmed SNPs, mutations were identified in genes previously known to be strongly associated with ASD such as SLCO1B1, ACADSB, TCF4, HCP5, MOCOS, SRD5A2, MCCC2, DCC, and PRKN while several other mutations are known to associate with autistic traits or other neurodevelopmental disorders. Some mutations were found in multiple patients and some patients carried multiple pathogenic/likely pathogenic mutations. These findings contribute to the identification of potential targets for therapeutic solutions in what is considered a genetically heterogeneous neurodevelopmental disorder.
Acamprosate calcium is supplied in an enteric-coated tablet for oral administration. Acamprosate calcium is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine, which is a structural analogue of the amino acid neurotransmitter γ-aminobutyric acid and the amino acid neuromodulator taurine. Its chemical name is 3-(Acetylamino)-1-propanesulfonic acid calcium salt (2:1). Its chemical formula is C10H20N2O8S2Ca and molecular weight is 400.48. Its structural formula is:

Acamprosate calcium, USP is a white odorless crystalline powder. It is freely soluble in water, and practically insoluble in absolute ethanol and dichloromethane.

Each acamprosate calcium delayed-release tablet contains acamprosate calcium 333 mg, equivalent to 300 mg of acamprosate. Inactive ingredients in acamprosate calcium delayed-release tablets include: colloidal silicon dioxide, glyceryl dibehenate, hypromellose, magnesium stearate, methacrylic acid copolymer type A, microcrystalline cellulose, propylene glycol and talc. In addition, the black imprinting ink for the tablets contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze. Sulfites were used in the synthesis of the drug substance and traces of residual sulfites may be present in the drug product.
Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
PROBLEM TO BE SOLVED: To make it possible to carry out the solubilization having suitability for living bodies or the extraction by means of forming reversed micelle by using a surfactant arising from organisms and natural oils and fats or their derivatives. SOLUTION: The surfactant originating from organisms [phospholipid surfactants, e.g. raw soybean lecithin or a mixture of soybean phosphatidylcholine (1 mole) and a fatty acid (0.4-4 moles of oleic acid) is added into natural oils and fats or their derivatives (fatty acid ethyl esters, e.g. ethyl oleate and ethyl linolate) used as the oil phase to form a reversed micelle. By incorporating slightly oil-soluble or oil-insoluble substances (e.g. protein and the like) into the water pull in this reversed micelle or the interface of reversed micelle, the solubilization capable of using in fields relating to foods and medicines or the extraction is carried out.
A wearable physiological monitoring system comprises commercially available off-the shelf components. With the growth of interrelated systems of computing devices, mechanical and digital machines, objects, animals or people connected by the Internet, there is a significant interest in the use of wearable sensors such as cell watches, and smart phones. These wearable sensors may be used to monitor physiological signals and provide health information. An edge-intelligent Internet based wearable assists in substance-abuse detection by monitoring and interpreting an individual's physiological signals on continuous basis. The wearable device helps in monitoring cravings and substance abuse of the individual and help the healthcare provider to start an early intervention as required. The proposed system is developed as a dedicated substance abuse wearable system. An example of a wearable device is a medical quality wearable which yielded a correlation of 0.89 for accelerometer measurements and 0.92 for average heart rate measurements in tests.
* Open the SOLOSEC packet by folding over the corner (marked by an arrow) and tearing across the top.
  * Sprinkle the entire contents of the SOLOSEC packet onto applesauce, yogurt or pudding [see Clinical Pharmacology (12.3)]. The granules will not dissolve. Consume all of the mixture within 30 minutes without chewing or crunching the granules. A glass of water may be taken after the administration of SOLOSEC to aid in swallowing.
  * The granules are not intended to be dissolved in any liquid.
  * Avoid consumption of alcoholic beverages and preparations containing ethanol or propylene glycol during treatment with SOLOSEC and for at least 2 days after completing therapy. [see Adverse Reactions (6.2), Drug Interactions (7.2), and Clinical Pharmacology (12.3)] .
Hypotension – Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (SeeWARNINGS andDOSAGE AND ADMINISTRATION.) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (SeeDOSAGE AND ADMINISTRATION.)

Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function. These effects are usually reversible. In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of lisinopril alone were compared to lisinopril given concomitantly with indomethacin, the use of indomethacin was associated with a reduced effect, although the difference between the two regimens was not significant.

Other Agents: Lisinopril has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. No meaningful clinically important pharmacokinetic interactions occurred when lisinopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of lisinopril.
Single-incision laparoscopic surgery is a surgical procedure in which multiple laparoscopic instruments are placed through a single small incision. It has the advantages of less surgical trauma, better cosmetic results and less postoperative pain compared with conventional laparoscopic surgery. However, the technical challenges and difficulties, including loss of triangulation, parallel coaxial effect, difficulty of achieving correct exposure, shared fulcrum, lack of ergonomic favorable position, etc. limited its widespread use. Robot-assisted laparoscopic surgery have significant advantages such as minimally invasive, delicate, and flexible, which can greatly expand the surgeon's surgical capabilities and effectively solve the various problems faced by traditional surgery. Therefore, robotic assisted single-port surgery is attracting increasing attention. This study is to investigate the safety of a novel single-port robotic system for general surgery.
LUNSUMIO can cause serious or severe tumor flare [see Adverse Reactions (6.1)].

Among patients who received LUNSUMIO at the recommended dosage in the clinical trial, tumor flare occurred in 4% of patients. Manifestations included new or worsening pleural effusions, localized pain and swelling at the sites of lymphoma lesions, and tumor inflammation.

Patients with bulky tumors or disease located in close proximity to airways or a vital organ should be monitored closely during initial therapy. Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare. If compression or obstruction develops, institute standard treatment of these complications.
A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
A process for the preservation of human red blood cells comprises forming a suspension of the cells in an aqueous glycerol-citrate, e.g. disodium citrate, medium, equivalent to that produced by suspending 100 ml. of packed red blood cells, containing 10 ml. of residual plasma, in 100 ml. of aqueous glycerol containing from 30 to 50 ml. of glycerol together with citrate ions derivable from 1.3 to 3.5 gm. trisodium citrate dihydrate, and storing the suspension at from -15 DEG  to -25 DEG  C.  The suspension is produced by mixing fresh human blood with an aqueous solution of disodium citrate, removing plasma and citrate solution and suspending the concentrated residue in the glycerol-citrate solution.  The pH may be adjusted from 6.5 to 8.0 by addition of one or more potassium hydrogen phosphates.  A statement of the prior art discloses storage of red blood cells for a limited period at 4 DEG  C. and a suspension of cells in a glycerol-saline solution for storage at -70 DEG  to -80 DEG  C.
Patients with low vitamin D3 levels receive cholecalciferol PO daily for 8 weeks in the absence of unacceptable toxicity. Patients undergo blood sample collection throughout the study.
The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
Mobile health technology, including smartphone apps and wearable monitors, has tremendous potential to transform clinical research. Recording of patient outcomes on a smartphone device and camera in the home setting can greatly reduce the number of in person research visits, saving tremendous costs, time, and effort associated with data entry. This also allows for easier recruitment of study subjects, who can be enrolled in geographic locations beyond academic research centers. After FDA approval of a therapy, mobile health technology can help researchers understand how that particular therapy is being used in a real-world setting, including frequency of use, adverse events, and impact of use on disease symptoms and patient quality of life. In this study, the investigators will create a mobile app to help the atopic dermatitis community understand the types of data and quality of data that can be gathered from atopic dermatitis patients longitudinally. A review of existing atopic dermatitis mobile apps on the market reveals they are consumer-oriented and may not be able to fully capture high-quality research data. The investigator proposed app is specifically geared for research, and thus fills an important gap. The research team will develop SkinTracker, a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting.
315,777. Hampshire, F. W., and Hampshire & Co. (1927), Ltd., F. W. April 16, 1928. Linings and internal fittings.-A receptacle A, of circular or oval section, for volatile inhalants or smelling salts is provided with a diaphragm A<2> of plaster of Paris or like porous material through which the liquid diffuses. The diaphragm A<2> is supported upon a flange A<3> within the container and may be formed by pouring pasty plaster of Paris upon a cardboard disc supported on the flange after the insertion of the liquid. Alternatively the receptacle may be provided with a porous lining formed integrally with the diaphragm, the liquid being introduced into the space so formed either before completion of the diaphragm or by percolation through the latter. The receptacle is closed, when not in use, by a screw or friction cap B.
Oral antidiabetics, esp. useful for treating subclinical and senile diabetes, contain an amino acid of formula : HOOC-CHNH2-X-COOH (I) (where X is an opt. branched 1-4C hydrocarbon residue) completely or partly in the form of an acid addn. salt (I) is pref. glutamic or aspartic acid and the salt-forming acid is pref. HCl or citric acid. The COOH gps. can also be completely or partly bonded with inorganic cations, pref. alkali(ne earth) metals or Zn. (I) may be combined with other oral hypoglycaemic agents, pref. phenformin and/or tolbutamide.
Transcutaneous Electrical Nerve Stimulation (TENS) was applied to the brachial plexus at the supraclavicular fossa (Erb's point) and to the radial nerve between the biceps and triceps in the spiral groove. The frequency was set at 10 Hz, and the intensity was adjusted to a level that elicited sensation without causing pain or muscle twitching, for a duration of 45 minutes, five days a week, totaling 20 sessions over four weeks, combined with standard upper extremity conservative occupational therapy training.